Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human VEGF189, 4x 50ug  

ActiveMax® Recombinant Human VEGF189, 4x 50ug

ActiveMax® Recombinant Human VEGF189, Ala 27 - Arg 215, produced in human 293 cells (HEK293), Tag free

Synonym: Recombinant, Human, Protein, VEGFA,VPF,

More details

VE9-H5214-250

Availability: within 7 days

1 400,00 €

Background
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. Mature human VEGF189 shares 88% aa sequence identity with mouse VEGF188. VEGF189 binds to heparan sulfate both on the cell surface and in the extracellular matrix (ECM) where it retains bioactivit. Furthermore, VEGF189 interacts with various receptors including VEGF R1, VEGF R2, Neuropilin-1, and Integrins aVb3, aVb5, a3b1, and a5b1.

Source
ActiveMax® Recombinant Human VEGF189 Protein (ActiveMax® Recombinant Human VEGF189) Ala 27 - Arg 215 was produced in human 293 cells (HEK293)

Molecular Characterization
ActiveMax® Recombinant Human VEGF189 contains no "tag", and has a calculated MW of 22 kDa. The predicted N-terminus is Ala 27. As a result of glycosylation, the reducing (R) protein migrates as 30 kDa, and the non-reducing (NR) protein migrates as 45-50 kDa (homodimer) in SDS-PAGE .

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.
Contact us for customized product form or formulation.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Immobilized ActiveMax® Human VEGF189 (Cat# VE9-H5214) at 2 μg/mL (100 μL/well) can bind VEGFR2 / R3-Fc with a linear range of 0.3-1.25 ng/mL.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).

References

(1) Byrne, A.M. et al., 2005, J. Cell. Mol. Med, 9(4):777-94.
(2) Robinson, C.J. et al., 2001, J. Cell. Sci. 114(Pt 5):853-65.
(3) Zelzer, E. et al., 2002, Development, 129(8):1893-904.

The following products could also be interesting for you: